Chugai Pharmaceutical is one of Japan's leading research-based pharmaceutical companies, operating as a majority-owned member of the Roche Group. The company specializes in oncology, transplantation, and bone and joint diseases, with a strong portfolio of biologics and antibody-based medicines. Chugai's affiliation with Roche provides access to global research capabilities and a pipeline of innovative compounds.

For international investors, Chugai Pharmaceutical represents a unique investment in Japan's pharmaceutical sector as a Roche subsidiary with independent listing status. The company's deep integration with Roche's global R&D and commercial infrastructure provides access to a world-class drug development platform, while its domestic Japanese operations contribute stable revenues. Chugai's oncology and immunology pipeline, developed in collaboration with the broader Roche Group, positions it at the forefront of innovative biologic medicine development in Japan.